drugset / Trial / NCT04337606
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed after chimeric antigen receptor T cells infusion. The purpose is to evaluate the safety and efficacy of the treatment with chidamide in combination with decitabine.
Timeline
- Start
- 2020-04-04
- Primary completion
- 2024-04-04
- Completion
- 2026-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Decitabine | Small molecule | 10 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |